Serial MRI in multiple sclerosis: A prospective pilot study of lesion load, whole brain volume and thalamic atrophy

Journal of Clinical Neuroscience

Volumn 11, Issue 2, 2004, Pages 153-158

  Taylor, I ^a   Butzkueven, H ^a   Litewka, L ^b   MacGregor, L R ^a   Szoeke, C ^a   Cook, M ^b   Mitchell, P ^a   Kilpatrick, T J ^a   Tubridy, Niall ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Atrophy; Magnetic resonance imaging; Multiple sclerosis; Thalamic volume

Indexed keywords

INTERFERON;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN INJURY; BRAIN SIZE; CLINICAL ARTICLE; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; SERIAL NUCLEAR MAGNETIC RESONANCE IMAGING; THALAMUS; THALAMUS ATROPHY;

EID: 1342346730     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(03)00145-0     Document Type: Article

References (25)

1. Lassmann H, Bruck W, Lucchinetti C, Rodriguez M. Remyelination in multiple sclerosis. Mult Scler 1997; 3(2): 133-136.
2. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42(5): 783-793.
3. Dalton CM, Brex PA, Jenkins R et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73(2): 141-147.
4. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53(8): 1698-1704.
5. Ge Y, Grossman RI, Udupa JK et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000; 214(3): 665-670.
6. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002; 125(Pt 2): 327-337.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278-285.
8. Arnold DL, Wolinsky JS, Matthews PM, Falini A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64(Suppl 1): S94-S101.
9. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. Eur J Neurol 2001; 8(1): 37-42.
10. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50(3): 389-400.
11. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52(5): 650-653.
12. Bakshi R, Benedict RH, Bermel RA et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002; 59(1): 62-68.
13. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121(Pt 1): 3-24.
14. Truyen L, van Waesberghe JH, van Walderveen MA et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47(6): 1469-1476.
15. van Walderveen MA, Lycklama ANGJ, Ader HJ et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001; 58(1): 76-81.
16. Losseff NA, Kingsley DP, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1996; 1(4): 218-222.
17. Kalkers NF, Bergers E, Castelijns JA et al. Optimizing the association between disability and biological markers in MS. Neurology 2001; 57(7): 1253-1258.
18. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285-294.
19. Ge Y, Grossman RI, Udupa JK et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000; 54(4): 813-817.
20. Molyneux PD, Kappos L, Polman C et al. The effect of interferon β-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon β-1b in secondary progressive multiple sclerosis. Brain 2000; 123(Pt 11): 2256-2263.
21. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3): 227-231.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452.
23. Bridle N, Pantelis C, Wood SJ et al. Thalamic and caudaate volumes in monozygotic twins discordant for schizophrenia. Aust N Z J Psychiatry 2002; 36(3): 347-354.
24. Filippi M, Paty DW, Kappos L et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995; 45(2): 255-260.
25. Gass A, Filippi M, Rodegher ME, Schwartz A, Comi G, Hennerici MG. Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI. Neurology 1998; 50(2): 548-550.